Реализованные проекты

Клиническая команда ARS и отдел регистрации препаратов состоит из профессионалов, многие годы работающих в данной сфере. ARS имеет значительный опыт в онкологии, неврологии, офтальмологии, гастроэнтерологии, инфекционных и сердечно-сосудистых заболеваниях, других областях.

Ниже Вы можете ознакомиться с конкретными примерами проектов компании:

MR – Market Research,
BE/PK - Bioequivalence / Pharmacokinetics,
TE – Therapeutic Equivalence,
MA – Marketing Authorization,
MMCT – Multinational Multicenter Clinical Trial

Allergology

Indication
Stage
Year completed
Product Type
IndicationPersisting and seasonal allergic rhinitis and conjunctivitis; hay fever (pollinosis); urticaria; allergic dermatitis
StageMA
Year completed2016
Product TypeINN - Levocetirizine
IndicationPersisting and seasonal allergic rhinitis and conjunctivitis; hay fever (pollinosis); urticaria; allergic dermatitis
StageBE/PK
Year completed2014
Product TypeINN - Levocetirizine

Antifungal

Indication
Stage
Year completed
Product Type
IndicationFungal lesions of the skin and mucous membranes
StageMA
Year completedpresent
Product TypeINN - Clotrimazole

Cardiovascular

Indication
Stage
Year completed
Product Type
IndicationOrphan: Thrombocytosis
StageMA
Year completedpresent
Product TypeINN - Anagrelide
IndicationPrevention of venous thrombosis and embolism in surgical interventions, treatment of unstable angina and myocardial infarction, etc.
StageMA
Year completedpresent
Product TypeBioanalogue - Enoxaparin sodium
IndicationPrevention of atherothrombotic complications; prevention of atherothrombotic and thromboembolic events, including stroke in atrial fibrillation (atrial fibrillation)
StageRenewal
Year completedpresent
Product TypeINN - Clopidogrel
IndicationAnticoagulants
StagePVG
Year completedpresent
Product TypeINN - Sulodexide
IndicationTreatment of symptoms of venous lymphatic insufficiency; symptomatic therapy of acute hemorrhoids
StageMA
Year completedpresent
Product TypeFDC - Diosmin + Hesperidin
IndicationEssential thrombocythemia
StageVariations + Renewal + GMP
Year completedpresent
Product TypeINN - Anagrelide
IndicationEssential arterial hypertension
StageBE/PK + MA
Year completed2018 + present
Product TypeINN - Olmesartan
IndicationArterial hypertension, others
StageBE/PK + MA
Year completed2018 + present
Product TypeINN - Telmisartan
IndicationSymptomatic treatment of intermittent claudication
StageMA
Year completed2018
Product TypeINN - Cilostazol
IndicationArterial hypertension, others
StageBE/PK
Year completed2018
Product TypeINN - Telmisartan
IndicationArterial hypertension, angina pectoris, dilated (non-ischemic) cardiomyopathy with severe chronic heart failure
StageVariation
Year completed2017
Product TypeINN - Amlodipine
IndicationPulmonary arterial hypertension
StageBE/PK
Year completed2017
Product TypeINN - Bosentan
IndicationArterial hypertension; prevention of recurrent stroke, stable coronary artery disease
StageRenewal
Year completed2017
Product TypeINN - Perindopril
IndicationHypercholesterolemia in the absence of the effect of diet, combined hypercholesterolemia and triglyceridemia, ischemic heart disease, prevention of myocardial infarction and stroke, atherosclerosis.
StageRenewal
Year completed2017
Product TypeINN - Simvastatin
IndicationHypertension, congestive heart failure, others
StageRenewal
Year completed2017
Product TypeINN - Lisinopril
IndicationEdematous syndrome of different genesis; arterial hypertension
StageMA
Year completed2017
Product TypeINN - Torasemide
IndicationPrevention of atherothrombotic complications in patients with myocardial infarction, ischaemic stroke, acute coronary syndrome
StageMA
Year completed2017
Product TypeINN - Clopidogrel
IndicationPrevention of atherothrombotic complications; prevention of atherothrombotic and thromboembolic events, including stroke in atrial fibrillation (atrial fibrillation)
StageBE/PK
Year completed2017
Product TypeINN - Clopidogrel
IndicationPrevention of venous thrombosis and embolism in surgical interventions, treatment of unstable angina and myocardial infarction, etc.
StageVariation
Year completed2016
Product TypeBioanalogue - Enoxaparin sodium
IndicationSymptomatic treatment of intermittent claudication
StagePhase III CT
Year completed2016
Product TypeINN - Cilostazol
IndicationHypertension, congestive heart failure, others
StageED price registration
Year completed2015
Product TypeINN - Lisinopril
IndicationHypertension, congestive heart failure, cardiomyopathy, others
StageED price registration
Year completed2015
Product TypeINN - Captopril
IndicationStable angina, chronic heart failure
StageMA
Year completed2015
Product TypeINN - Ivabradine
IndicationArterial hypertension; chronic heart failure; arterial hypertension in children and adolescents
StageMA
Year completed2015
Product TypeINN - Valsartan
IndicationStable angina, chronic heart failure
StageBE/PK
Year completed2015
Product TypeINN - Ivabradine
IndicationArterial hypertension
StageMA
Year completed2015
Product TypeFDC - Losartan + Hydrochlorothiazide
IndicationEdematous syndrome of various origins, arterial hypertension
StageBE/PK
Year completed2014
Product TypeINN - Torasemide
IndicationСomplex therapy of unstable angina and myocardial infarction without q wave
StagePhase III CT
Year completed2014
Product TypeBioanalogue - Enoxaparin sodium
IndicationNeuroprotection, improvement of cerebral circulation, peripheral and microcirculation, etc.
StagePreclinical
Year completed2013
Product TypeBotanical drug - Vasoprotective drug
IndicationPrevention of atherothrombotic complications in patients with myocardial infarction, ischaemic stroke, acute coronary syndrome
StageMA
Year completed2013
Product TypeINN - Clopidogrel
IndicationChronic heart failure
StageMA
Year completed2012
Product TypeINN - Bisoprolol
IndicationArterial hypertension, ischemic heart disease, chronic heart failure
StageMA
Year completed2012
Product TypeINN - Nebivolol
IndicationArterial hypertension
StageMA
Year completed2011
Product TypeFDC - Hydrochlorothiazide + Losartan
IndicationArterial hypertension, ischemic heart disease
StageMA
Year completed2011
Product TypeINN - Bisoprolol
IndicationArterial hypertension, ischemic heart disease
StageMA
Year completed2011
Product TypeINN - Nebivolol
IndicationArterial hypertension
StageMA
Year completed2011
Product TypeINN - Indapamide

CNS (neurology, psychiatry)

Indication
Stage
Year completed
Product Type
IndicationNeuropathic pain, epilepsy, fibromyalgia, generalized anxiety disorder
StageMA
Year completedpresent
Product TypeINN - Pregabalin
IndicationNonsteroidal anti-inflammatory drug
StageMA
Year completedpresent
Product TypeINN - Nimesulide
IndicationSleep disorder
StagePhase III CT + MA
Year completedpresent
Product TypeNew FDC
IndicationSchizophrenia, bipolar disorder
StageBE/PK + MA
Year completedpresent
Product TypeINN - Aripiprazole
IndicationAdjunctive therapy in patients with degenerative brain diseases
StagePhase III CT + PVG
Year completedpresent
Product TypeBranded pharmaceutical
IndicationPsychoses, including schizophrenia and manic conditions; depression during menopause; others
StageBE/PK
Year completed2019
Product TypeINN - Chlorprothixen
IndicationDepression
StageBE/PK (medical writing)
Year completed2019
Product TypeINN - Agomelatine
IndicationNeuropathic pain, epilepsy, fibromyalgia, generalized anxiety disorder
StageBE/PK
Year completed2019
Product TypeINN - Pregabalin
IndicationAlzheimer's Disease
StageBE/PK + MA
Year completed2019
Product TypeINN - Donepezil HCL
IndicationRelapsing-remitting multiple sclerosis
StageBE/PK
Year completed2018
Product TypeINN - Fingolimod
IndicationModerate to severe postoperative pain (within 48 hours after uncomplicated appendectomy, cholecystectomy, herniotomy, herniorraphy or phlebectomy)
StagePhase III CT
Year completed2018
Product TypeINN - Ketorolac trometamol
IndicationTraumatic brain injury, chronic cerebrovascular insufficiency, dementia, ischemic stroke, functional disorders of the Central nervous system, memory impairment, confusion, disorientation, decreased motivation, initiative and concentration, senile pseudomelancholy
StageVariation
Year completed2017
Product TypeINN - Choline alfoscerate
IndicationSleep disorder
StageVariation
Year completed2017
Product TypeINN - Zolpidem
IndicationAnxiety
StagePhase III CT
Year completed2017
Product TypeDietary supplement - Sedative
IndicationAcute and chronic psychoses, including schizophrenia
StageBE/PK
Year completed2017
Product TypeINN - Quetiapine
IndicationTraumatic brain injury, chronic cerebrovascular insufficiency, dementia (Alzheimer's type, senile, mixed forms), ischemic stroke, Huntington's chorea, functional disorders of central nervous system, impaired memory, confusion, disorientation, decreased motivation, initiative and concentration
StageED price registration
Year completed2017
Product TypeINN - Choline alfoscerate
IndicationPain syndrome of moderate and strong intensity
StageMA
Year completed2016
Product TypeINN - Tramadol
IndicationNeuropathic pain, generalized anxiety disorder, fibromyalgia, partial seizures
StageMA
Year completed2016
Product TypeINN - Pregabalin
IndicationNeuropathic pain, epilepsy, fibromyalgia, generalized anxiety disorder
StageBE/PK
Year completed2015
Product TypeINN - Pregabalin
IndicationEpilepsy with the partial with secondary generalization or not, or generalized tonic-clonic seizures, Lennox-Gastaut syndrome
StageMA
Year completed2015
Product TypeINN - Topiramate
IndicationNeuropathic pain, epilepsy
StageMA
Year completed2013
Product TypeINN - Gabapentin
IndicationModerate and severe depression and its prevention, panic disorder with/without agoraphobia
StageMA
Year completed2013
Product TypeINN - Citalopram
IndicationEpilepsy with the partial with secondary generalization or not, or generalized tonic-clonic seizures, Lennox-Gastaut syndrome
StageMA
Year completed2013
Product TypeINN - Topiramate
IndicationStrong and moderate pain
StageMA
Year completed2013
Product TypeINN - Ketorolac
IndicationPartial seizures with secondary generalization or without in patients with Epilepsy
StageMA
Year completed2012
Product TypeINN - Levetiracetam
IndicationRelieving pain
StageMA
Year completed2011
Product TypeINN - Ketorolac
IndicationAnxiety
StagePreclinical
Year completed2010
Product TypeDietary supplement - Sedative

Contrast media

Indication
Stage
Year completed
Product Type
IndicationAngiocardiography, aortography, angiography of the lungs, head, neck, brain, abdomen, kidneys, research collateral circulation, venography, excretory urography, myelography, etc.
StageMA
Year completed2017
Product TypeINN - Iohexol

Dermatology

Indication
Stage
Year completed
Product Type
IndicationAtopic dermatitis
StagePhase III CT
Year completed2015
Product TypeINN - Pimecrolimus

Diagnostics

Indication
Stage
Year completed
Product Type
IndicationCardiovascular / Hepatology / Ophthalmology
StageVariations + PVG
Year completedpresent
Product TypeINN - Indocyanine green

Gastroenterology

Indication
Stage
Year completed
Product Type
IndicationErosive reflux esophagitis, peptic ulcer and duodenal ulcer, prevention of relapse of peptic ulcer syndrome Zollinger-Ellison, others
StageMA
Year completedpresent
Product TypeINN - Esomeprazole
IndicationDyspeptic disorders
StageMA
Year completedpresent
Product TypeINN - Domperidone
IndicationDeficiency of pancreatic enzymes
StageMA
Year completedpresent
Product TypeINN - Pancreatin
IndicationDuodenal ulcer, gastric ulcer, others
StageBE/PK
Year completed2018
Product TypeINN - Pantoprazole
IndicationErosive reflux esophagitis, peptic ulcer and duodenal ulcer, prevention of relapse of peptic ulcer syndrome Zollinger-Ellison, others
StageBE/PK
Year completed2017
Product TypeINN - Esomeprazole
IndicationPeptic ulcer and duodenal ulcers, others
StageMA
Year completed2016
Product TypeINN - Omeprazole
IndicationPeptic ulcer and duodenal ulcer, ulcer anastomosis, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome
StageMA
Year completed2015
Product TypeINN - Rabeprazole
IndicationAcute peptic ulcer and duodenal ulcer, gastroesophageal reflux disease; pathological hypersecretion, incl. the syndrome of Zollinger-Ellison
StageBE/PK
Year completed2015
Product TypeINN - Rabeprazole Sodium
IndicationUlcerative colitis, Crohn's disease
StageMA
Year completed2014
Product TypeINN - Mesalazine
IndicationPurgation before radiologic or endoscopic examinations and surgical procedures
StageMA
Year completed2014
Product TypeBranded pharmaceutical
IndicationUlcerative proctosigmoiditis, left-sided ulcerative colitis.
StageMA
Year completed2014
Product TypeINN - Mesalazine
IndicationPeptic ulcer and duodenal ulcer; anastomotic ulcer; gastroesophageal reflux disease (GERD); Zollinger-Ellison syndrome, others
StageBE/PK
Year completed2014
Product TypeINN - Rabeprazole
IndicationChronic constipation, hypo- and intestinal atony; facilitating emptying of the bowel
StagePreclinical
Year completed2013
Product TypeBotanical drug - Laxative drug
IndicationAntiulcer therapy
StageMA
Year completed2012
Product TypeINN - Rebamipide
IndicationAcute duodenal ulcer, gastroesophageal reflux disease (GERD)
StageMA
Year completed2011
Product TypeINN - Rabeprazole
IndicationSpasms of smooth muscles of internal organs
StageMA
Year completed2011
Product TypeFDC - Metamizole sodium + Pitofenone + Fenpiverinium bromide
IndicationSpasm of smooth muscle in diseases of the biliary tract and urinary tract; spasms of smooth muscles of the gastrointestinal tract; spastic colitis, irritable bowel syndrome; dysmenorrhea
StageMA
Year completed2011
Product TypeINN - Drotaverine

General

Indication
Stage
Year completed
Product Type
IndicationProduction of infusions, extracts and dosage forms for external use
StageED price registration
Year completed2018
Product TypeINN - Ethanol
IndicationN/A
StageMA
Year completed2015
Product TypeWater for injection

Gynecology / Obstetrics / Reproductive Health

Indication
Stage
Year completed
Product Type
IndicationNonspecific vaginitis caused by Candida in the acute stage of the disease
StageDSUR
Year completedpresent
Product TypeBranded pharmaceutical
IndicationContraception
StageBE/PK
Year completed2019
Product TypeFDC - Desogestrel + Ethinylestradiol
IndicationContraception
StageBE/PK (medical writing)
Year completed2019
Product TypeFDC - Drospirenone+Ethinyl Estradiol
IndicationContraception
StageBE/PK (medical writing)
Year completed2019
Product TypeFDC - Gestodene+Ethinyl Estradiol
IndicationContraception
StageBE/PK (medical writing)
Year completed2019
Product TypeFDC - Chlormadinone+Ethinyl Estradiol
IndicationContraception
StageBE/PK (medical writing)
Year completed2019
Product TypeFDC - Drospirenone+Ethinyl Estradiol
IndicationContraception
StageBE/PK (medical writing)
Year completed2019
Product TypeFDC - Gestodene+Ethinyl Estradiol
IndicationNonspecific vaginitis caused by Candida in the acute stage of the disease
StagePhase III CT
Year completed2018
Product TypeBranded pharmaceutical
IndicationRelief of manifestations of postmenopausal syndrome
StagePhase III CT / MW
Year completed2017
Product TypeBranded pharmaceutical (botanical)
IndicationPredmenstrualnyj syndrome, fibrocystic disease of the breast; the premenopausal, menopause, others
StageRenewal
Year completed2016
Product TypeINN - Progesterone
IndicationErectile dysfunction
StageMA
Year completed2016
Product TypeINN - Sildenafil
IndicationErectile dysfunction
StageBE/PK
Year completed2016
Product TypeINN - Sildenafil
IndicationContraception
StageBE/PK
Year completed2015
Product TypeFDC - Dienogest + Ethinylestradiol
IndicationAnovulation, controlled ovarian hyperstimulation; stimulation of spermatogenesis in case of azoospermia or oligoasthenospermia
StageMA
Year completed2014
Product TypeBioanalogue - Menotropins
IndicationErectile dysfunction
StagePreclinical
Year completed2014
Product TypeINN - Sildenafil
IndicationHypofunction of sexual glands; ovulation induction due to anovulation or impaired maturation of follicles; gipogonadotropny hypogonadism; delayed puberty caused by a lack of gonadotropic pituitary function; cryptorchidism; others
StagePreclinical
Year completed2013
Product TypeBioanalogue - Choronic Gonadotrophin
IndicationErectile dysfunction
StageBE/PK
Year completed2013
Product TypeINN - Sildenafil
IndicationAnovulation, controlled ovarian hyperstimulation
StageMA
Year completed2013
Product TypeBioanalogue - Urofollitropin
IndicationContraception in women with symptoms of androgenization
StageMA
Year completed2013
Product TypeFDC - Cyproterone + Ethinylestradiol

Hematology / Cardiovascular

Indication
Stage
Year completed
Product Type
IndicationDeficiency of coagulation factor
StageVariations
Year completed2017
Product TypeBioanalogue - Blood coagulation factor VIII
IndicationBleedings; aphthous stomatitis, angina, laringofaringit, hereditary angioedema, eczema, allergic dermatitis, urticaria, medicinal and toxic rash
StageMA
Year completed2017
Product TypeINN - Tranexamic acid
IndicationDeep vein thrombosis, pulmonary embolism, coronary artery disease, thrombophlebitis, unstable angina, acute myocardial infarction, atrial fibrillation, disseminated intravascular coagulation
StageMA
Year completed2013
Product TypeBioanalogue - Heparin

Hepatology

Indication
Stage
Year completed
Product Type
IndicationUncomplicated gallstone disease; chronic hepatitis; cholestatic liver disease; nonalcoholic fatty liver disease; alcoholic liver disease; chronic viral hepatitis; biliary dyskinesia; the biliary replace gastritis and reflux esophagitis
StageBE/PK
Year completed2017
Product TypeINN - Ursodeoxycholic acid
IndicationFatty degeneration of the liver; acute and chronic hepatitis, cirrhosis, liver cell necrosis, hepatic coma and precoma, toxic liver damage; toxemia of pregnancy; pre - and post-operative treatment, especially during operations in the field of hepatobiliary zone; psoriasis (as adjunctive therapy); radiation syndrome
StageMA
Year completed2014
Product TypeINN - Natural phospholipids

Hepatology / Infectious diseases

Indication
Stage
Year completed
Product Type
IndicationChronic viral hepatitis B
StageMA
Year completed2019
Product TypeOriginal drug (peptide)
IndicationChronic hepatitis B, C
StageMA
Year completed2016
Product TypeBioanalogue - Peginterferon alfa-2b
IndicationChronic hepatitis B, C
StagePhase III CT
Year completed2014
Product TypeBioanalogue - Peginterferon

Immunology

Indication
Stage
Year completed
Product Type
IndicationTreatment of herpetic diseases of the urogenital tract
StageVariation
Year completed2018
Product TypeNovel - complex of natural antimicrobial peptides and cytokines
IndicationPrevention of acute graft rejection in patients with allogeneic kidney transplants receiving basic immunosuppressive therapy with cyclosporine
StageBE/PK
Year completed2017
Product TypeINN - Mycophenolic acid
IndicationStrengthening the immune system; as a source of vitamin C; antibiotic therapy of chronic infectious diseases
StageMA
Year completed2011
Product TypeBotanical drug - Immunostimulant

Infectious / Inflammatory diseases

Indication
Stage
Year completed
Product Type
IndicationInfectious-inflammatory diseases caused by one or more pathogens sensitive to Meropenem
StageNew manufacturing site
Year completedpresent
Product TypeINN - Meropenem
IndicationInfectious and inflammatory diseases: meningitis, lower and upper respiratory tracts, urinary tract, bones, joints, skin and soft tissues, pelvic organs, uncomplicated gonorrhea, peritonitis, sepsis, intraabdominal infections, endocarditis, Lyme disease (borreliosis); infection caused by immunodeficiency; prevention of infections after surgery
StagePhase III CT
Year completed2016
Product TypeFDC - Cefotaxime + Sulbactam
IndicationInfectious-inflammatory diseases: pneumonia; complicated infections of skin and soft tissues; uncomplicated infections of skin and soft tissue ; infections not sensitive to vancomycin, caused by Enterococcus faecium, including bacteremia
StageBE/PK
Year completed2015
Product TypeINN - Linezolid
IndicationInfectious and inflammatory diseases: infection of the CNS (meningitis), lower and upper respiratory tracts, urinary tract, bones, joints, skin and soft tissues, pelvic organs, uncomplicated gonorrhea, peritonitis, sepsis, intraabdominal infections, endocarditis, Lyme disease (borreliosis); infection caused by immunodeficiency; prevention of infections after surgery
StagePhase III CT
Year completed2015
Product TypeFDC - Ceftriaxone + Sulbactam
IndicationPneumonia, appendicitis, peritonitis, pyelonephritis, pyelitis, bacterial meningitis, septicaemia, others
StageMA
Year completed2015
Product TypeINN - Meropenem
IndicationPneumonia, appendicitis, peritonitis, pyelonephritis, pyelitis, bacterial meningitis, septicaemia, others
StageMA
Year completed2015
Product TypeINN - Meropenem
IndicationBacterial infections caused by pathogens susceptible to the FDC: infections of upper and lower respiratory tract; urinary tract infections, infections of the female genital organs, gonorrhea; infections of skin and soft tissues; infections of bones and joints; septic abortion, puerperal sepsis, septicaemia, peritonitis, intraabdominal sepsis, postoperative infection
StageMA
Year completed2015
Product TypeFDC - Amoxicillin + Clavulanic acid
IndicationInfectious-inflammatory diseases: meningitis, lower and upper respiratory tract, urinary tract, bones, joints, skin and soft tissues, of pelvic organs; peritonitis, sepsis, endocarditis, gonorrhea, infected wounds and burns, intraabdominal infections, Salmonella, Lyme disease, infections caused by immunodeficiency
StagePreclinical
Year completed2014
Product TypeINN - Cefotaxime
IndicationInfectious-inflammatory diseases: sepsis, meningitis, typhoid fever, salmonellosis, disseminated Lyme borreliosis, infection of abdominal cavity, infections of bones, joints, soft tissues, skin and wound infections; infections in patients with reduced immunity, infections of kidneys and urinary tract, lower and upper respiratory tract infections; urogenital infections
StagePreclinical
Year completed2014
Product TypeINN - Ceftriaxone
IndicationInfectious-inflammatory diseases caused by sensitive to moxifloxacin microorganisms: acute sinusitis; exacerbation of chronic bronchitis; community-acquired pneumonia; infections of skin and soft tissues; complicated intraabdominal infections
StageMA
Year completed2014
Product TypeINN - Moxifloxacin
IndicationInfectious-inflammatory diseases caused by sensitive to ofloxacin by micro-organisms: lower respiratory tract, ENT organs; skin and soft tissues; bones and joints; abdominal and biliary tract; kidneys, urinary tract, prostate gland and urethra; genital and pelvic organs; septicaemia; prevention of infections in patients with impaired immune status
StageMA
Year completed2014
Product TypeINN - Ofloxacin
IndicationInfectious-inflammatory diseases caused by sensitive to Meropenem micro-organisms: lower respiratory infection; intraabdominal infections; infections of urinary tract; infections of skin and soft tissue; bacterial meningitis; septicaemia, infectious-inflammatory diseases of the pelvic organs
StageMA
Year completed2014
Product TypeINN - Meropenem
IndicationInfectious-inflammatory diseases caused by sensitive to moxifloxacin microorganisms: acute sinusitis; chronic bronchitis; pneumonia; infections of skin and soft tissues; complicated intra-abdominal infections; uncomplicated infections of the pelvic organs
StageBE/PK
Year completed2013
Product TypeINN - Moxifloxacin
IndicationInfectious-inflammatory diseases caused by sensitive to moxifloxacin microorganisms: acute sinusitis; chronic bronchitis; pneumonia; infections of skin and soft tissues; complicated intra-abdominal infections; uncomplicated infections of the pelvic organs
StageBE/PK
Year completed2013
Product TypeINN - Moxifloxacin
IndicationInfectious-inflammatory diseases caused by sensitive to levofloxacin by micro-organisms
StageMA
Year completed2011
Product TypeINN - Levofloxacin
IndicationInfectious-inflammatory diseases caused by sensitive to levofloxacin by micro-organisms
StageMA
Year completed2011
Product TypeINN - Levofloxacin

Infectious diseases

Indication
Stage
Year completed
Product Type
IndicationBacterial infections of different localization caused by sensitive pathogens
StageMA
Year completedpresent
Product TypeFDC - Ampicillin + Sulbactam
IndicationInfections of the lower respiratory tract; infections of ENT organs; infections of the biliary tract, intestinal infection
StageMA
Year completedpresent
Product TypeFDC - Amoxicillin + Sulbactam
IndicationIntra-abdominal infections, infections of the lower respiratory tract, genitourinary system, bones and joints, skin and soft tissues, pelvic organs, sepsis, bacterial endocarditis, prevention of postoperative infections, mixed infections, nosocomial infections, etc.
StageMA
Year completedpresent
Product TypeFDC - Imipenem + Cilastatin
IndicationBacterial infections of the respiratory tract, pelvic organs, urinary tract, bones and joints, skin and soft tissues, abdominal infections, sepsis, endocarditis caused by sensitive microorganisms
StageMA
Year completedpresent
Product TypeINN - Cefoxitin
IndicationBacterial infections of the upper and lower respiratory tract; pneumonia; infections of the urinary tract and genitals, skin and soft tissues, bones and joints; others
StageMA
Year completedpresent
Product TypeINN - Cefoperazone
IndicationComplicated skin and soft tissue infections caused by sensitive strains of the following gram-positive and gram-negative microorganisms
StageMA
Year completedpresent
Product TypeINN - Ceftaroline fosamil
IndicationTreatment of infections caused by aerobic gram-negative microorganisms
StageMA
Year completedpresent
Product TypeINN - Aztreonam
IndicationBacterial infections caused by sensitive microorganisms
StageMA
Year completedpresent
Product TypeINN - Cefuroxime
IndicationInfections of the respiratory and urinary tract, skin and soft tissue, abdominal, gynecological; septicemia, infection on the background of immunodeficiency, bacterial meningitis in children, prevention of infections in abdominal surgical operations
StageMA
Year completedpresent
Product TypeINN - Cefepime
IndicationUrinary tract infections
StageMA
Year completedpresent
Product TypeINN - Fosfomycin
IndicationInfectious and inflammatory diseases caused by sensitive to combination of Ceftriaxone with sulbactam pathogens
StageMA
Year completedpresent
Product TypeFDC - Ceftriaxone + Sulbactam
IndicationInfections caused by microorganisms sensitive to the combination of cefoperazone + sulbactam
StageMA
Year completedpresent
Product TypeFDC - Cefoperazone + Sulbactam
IndicationComplicated skin and soft tissue infections in adults caused by sensitive aerobic gram-positive bacteria; bacteremia caused by Staphylococcus aureus
StageMA
Year completedpresent
Product TypeINN - Daptomycin
IndicationBacterial infections of different localization caused by sensitive pathogens
StageMA
Year completedpresent
Product TypeFDC - Ampicillin + Sulbactam
IndicationInfectious and inflammatory diseases caused by strains of microorganisms sensitive to amoxicillin
StageMA
Year completedpresent
Product TypeFDC - Amoxicillin + Sulbactam
IndicationAs monotherapy or in combination with other antiretroviral agents for the treatment of infections caused by human immunodeficiency virus-1 (HIV-1)
StageMA
Year completedpresent
Product TypeFDC - Efavirenz + Emtricitabine + Tenofovir
IndicationChronic hepatitis in adults
StageMA
Year completedpresent
Product TypeINN - Entecavir
IndicationHIV-1 infection
StageMA
Year completedpresent
Product TypeINN - Saquinavir
IndicationARVI
StageMA
Year completedpresent
Product TypeFDC - Paracetamol 325 mg + Phenylephrine + Pheniramine + Ascorbic acid
IndicationARVI
StageMA
Year completedpresent
Product TypeFDC - Paracetamol 650 mg + Phenylephrine + Pheniramine + Ascorbic acid
IndicationAntifungal
StageBE/PK
Year completedpresent
Product TypeINN - Posaconazole
IndicationAcute respiratory diseases
StageMA
Year completedpresent
Product TypeFDC - Paracetamol + Phenylephrine + Pheniramine + Caffeine
IndicationFungal infections of the skin, etc.
StageMA
Year completedpresent
Product TypeINN - Naftifine
IndicationHIV/AIDS
StageBE/PK
Year completedpresent
Product TypeINN - Efavirenz
IndicationInfectious and inflammatory diseases caused by strains of microorganisms sensitive to amoxicillin
StageRenewal
Year completed2018
Product TypeFDC - Amoxicillin + Clavulanic acid
IndicationInfectious-inflammatory diseases: sepsis, meningitis, typhoid fever, salmonellosis, disseminated Lyme borreliosis, infection of abdominal cavity, infections of bones, joints, soft tissues, skin and wound infections; infections in patients with reduced immunity, infections of kidneys and urinary tract, lower and upper respiratory tract infections; urogenital infections
StageMA
Year completed2018
Product TypeINN - Ceftriaxone
IndicationHospital-acquired (nosocomial) pneumonia; complicated intra-abdominal infections; complicated urinary system infections
StageMA
Year completed2018
Product TypeINN - Doripenem
IndicationCommunity-acquired and nosocomial bacterial infections caused by susceptible microorganisms: pneumonia, bronchitis, lung abscess, empyema; urinary tract infections; infections of skin and soft tissue; intra-abdominal infections; gynecological infections; septicemia; febrile neutropenia; bacterial meningitis in children; prevention of infections in abdominal surgery
StageMA
Year completed2018
Product TypeFDC - Cefepime + Sulbactam
IndicationСorneal ulcers and infections of the anterior segment of the eyeball and its adnexa caused by susceptible to ciprofloxacin bacteria in adults, newborns, babies and infants, children and adolescents
StagePVG
Year completed2018
Product TypeINN - Ciprofloxacin
IndicationProtozoal infections, infections of bones and joints, сentral nervous system, bacterial endocarditis, pneumonia, empyema and lung abscess caused by Bacteroides spp.; infection of the abdominal cavity, infections of the pelvic organs, infections of skin and soft tissues caused by Bacteroides spp. (including B. fragilis), Clostridium spp., Peptococcus spp., Peptostreptococcus spp.; septicemia caused by Bacteroides spp. ; gastritis or peptic ulcer of the duodenum associated with Helicobacter pylori, others
StagePVG
Year completed2018
Product TypeINN - Metronidazole
IndicationHIV/AIDS
StageBE/PK
Year completed2018
Product TypeINN - Atazanavir
IndicationCytomegalovirus disease
StageMA
Year completed2018
Product TypeINN - Ganciclovir
IndicationBacterial diarrhea
StageMA
Year completed2018
Product TypeINN - Nifuroxazide
IndicationChronic hepatitis C
StageBE/PK
Year completed2018
Product TypeINN - Sofosbuvir
IndicationHIV-1 infection
StageBE/PK
Year completed2018
Product TypeINN - Saquinavir
IndicationHIV/AIDS
StageBE/PK
Year completed2018
Product TypeFDC - Abacavir + Lamivudine + Zidovudine
IndicationInfections caused by microorganisms sensitive to the combination of cefoperazone + sulbactam
StageRenewal
Year completed2017
Product TypeFDC - Cefoperazone + Sulbactam
IndicationInfectious and inflammatory diseases: meningitis, lower and upper respiratory tracts, urinary tract, bones, joints, skin and soft tissues, pelvic organs, uncomplicated gonorrhea, peritonitis, sepsis, intraabdominal infections, endocarditis, Lyme disease (borreliosis); infection caused by immunodeficiency; prevention of infections after surgery
StageMA
Year completed2017
Product TypeFDC - Cefotaxime + Sulbactam
IndicationHIV-1, hepatitis B
StageBE/PK
Year completed2017
Product TypeINN - Tenofovir
IndicationHIV/AIDS
StageBE/PK
Year completed2017
Product TypeINN - Darunavir
IndicationHIV infection in adults and children older than 3 years in combination therapy
StageBE/PK
Year completed2017
Product TypeINN - Ritonavir
IndicationChronic hepatitis in adults
StageBE/PK
Year completed2017
Product TypeINN - Entecavir
IndicationDysentery vaccine against Shigella flexneri (bacterial infectious disease)
StagePhase II CT
Year completed2017
Product TypeVaccine
IndicationAcute pyelonephritis
StagePhase III CT
Year completed2017
Product TypeFDC - Cefepime + Sulbactam
IndicationInfectious diseases of respiratory tract infections in patients with cystic fibrosis; ENT infections, skin and soft tissue, urinary tract, others
StageRenewal
Year completed2017
Product TypeINN - Ceftazidime
IndicationBacterial infections caused by susceptible microorganisms
StageRenewal
Year completed2017
Product TypeINN - Clarithromycin
IndicationSystemic and/or local bacterial infections caused by sensitive to tazobactam and piperacillin microorganisms
StageRenewal
Year completed2017
Product TypeFDC - Piperacillin + Tazobactam
IndicationCommunity-acquired pneumonia; complicated infections of skin and soft tissue, complicated intraabdominal infections
StageRenewal
Year completed2017
Product TypeINN - Moxifloxacin
IndicationHIV/AIDS
StageMA
Year completed2017
Product TypeFDC - Zidovudine + Lamivudine
IndicationInfectious-inflammatory diseases caused by sensitive to ofloxacin by micro-organisms: lower respiratory tract, ENT organs; skin and soft tissues; bones and joints; abdominal and biliary tract; kidneys, urinary tract, prostate gland and urethra; genital and pelvic organs; septicaemia; prevention of infections in patients with impaired immune status
StageMA
Year completed2017
Product TypeINN - Ofloxacin
IndicationHIV/AIDS
StageMA
Year completed2017
Product TypeFDC - Abacavir + Lamivudine
IndicationHepatitis B
StageVariations
Year completed2017
Product TypeBioanalogue - Human immunoglobulin against hepatitis B
IndicationCytomegalovirus infection, HIV
StageVariations
Year completed2017
Product TypeBioanalogue - Anticytomegalovirus human immunoglobulin
IndicationBacterial infections and immunodeficiency
StageVariations
Year completed2017
Product TypeBioanalogue - Immunoglobulin human normal {IgA+IgG+IgM}
IndicationBacterial infections and immunodeficiency
StageVariations
Year completed2017
Product TypeBioanalogue - Immunoglobulin human normal
IndicationSymptomatic therapy of infectious and inflammatory diseases (SARS, influenza), accompanied by high fever, chills, body aches, headache and muscle pain, runny nose, nasal congestion, sneezing
StageBE/PK
Year completed2017
Product TypeFDC - Paracetamol + Phenylephrine + Chlorphenamine maleate
IndicationUrinary tract infections: pyelitis, pyelonephritis, cystitis, urethritis
StageMA
Year completed2017
Product TypeINN - Nitrofurantoin
IndicationHIV/AIDS
StageBE/PK
Year completed2017
Product TypeINN - Lamivudine
IndicationHIV/AIDS
StageBE/PK
Year completed2016
Product TypeFDC - Lamivudine + Zidovudine
IndicationInfections of the respiratory and urinary tract, skin and soft tissue, abdominal, gynecological; septicemia, infection on the background of immunodeficiency, bacterial meningitis in children, prevention of infections in abdominal surgical operations
StageRenewal
Year completed2016
Product TypeINN - Cefepime
IndicationPrevention of influenza
StageBE/PK
Year completed2016
Product TypeINN - Oseltamivir
IndicationCommunity-acquired pneumonia
StagePhase III CT
Year completed2016
Product TypeFDC - Cefotaxime + Sulbactam
IndicationInfectious-inflammatory diseases caused by sensitive to levofloxacin by micro-organisms
StageBE/PK
Year completed2016
Product TypeINN - Levofloxacin
IndicationInfectious-inflammatory diseases caused by agents susceptible to vancomycin
StageMA
Year completed2016
Product TypeINN - Vancomycin
IndicationInfections of the respiratory and urinary tract, skin and soft tissue, abdominal, gynecological; septicemia, infection on the background of immunodeficiency, bacterial meningitis in children, prevention of infections in abdominal surgical operations
StageMA
Year completed2016
Product TypeINN - Cefepime
IndicationInfectious-inflammatory diseases, caused by susceptible to linezolid aerobic and anaerobic gram-positive microorganisms: community-acquired pneumonia caused by Streptococcus pneumoniae; hospital-acquired pneumonia; complicated infections of skin and soft tissues; uncomplicated skin infections and soft tissue infections caused by resistant to vancomycin Enterococcus faecium, accompanied by bacteremia as well
StageMA
Year completed2016
Product TypeINN - Linezolid
IndicationDysentery vaccine against Shigella flexneri (bacterial infectious disease)
StagePhase I CT / MW
Year completed2016
Product TypeVaccine
IndicationAs monotherapy or in combination with other antiretroviral agents for the treatment of infections caused by human immunodeficiency virus-1 (HIV-1)
StageBE/PK
Year completed2016
Product TypeFDC - Efavirenz + Emtricitabine + Tenofovir
IndicationChronic hepatitis in adults
StageBE/PK
Year completed2016
Product TypeINN - Entecavir
IndicationCMV retinitis in adults with AIDS, prevention of CMV infection after transplantation of solid organs
StageMA
Year completed2016
Product TypeINN - Valganciclovir
IndicationInfectious-inflammatory diseases caused by microorganisms sensitive to the drug
StageMA
Year completed2016
Product TypeINN - Levofloxacin
IndicationHIV-1 infection
StageMA
Year completed2016
Product TypeFDC - Tenofovir + Emtricitabine
IndicationInfections of skin and mucous membranes caused by HSV (herpes genitalis), labially herpes (herpes labialis); prevention of infections caused by cytomegalovirus (CMV), and diseases after transplantation of parenchymal organs, shingles (herpes zoster) and ophthalmic zoster virus
StageMA
Year completed2016
Product TypeINN - Valganciclovir
IndicationInfectious-inflammatory diseases caused by microorganisms sensitive to moxifloxacin
StageMA
Year completed2016
Product TypeINN - Moxifloxacin
IndicationCommunity-acquired pneumonia
StagePhase III CT
Year completed2015
Product TypeFDC - Ceftriaxone + Sulbactam
IndicationAs monotherapy or in combination with other antiretroviral agents for the treatment of infections caused by human immunodeficiency virus-1 (HIV-1)
StageBE/PK
Year completed2015
Product TypeFDC - Efavirenz + Emtricitabine + Tenofovir
IndicationInfectious-inflammatory diseases, caused by susceptible to linezolid aerobic and anaerobic gram-positive microorganisms: community-acquired pneumonia caused by Streptococcus pneumoniae; hospital-acquired pneumonia; complicated infections of skin and soft tissues; uncomplicated skin infections and soft tissue infections caused by resistant to vancomycin Enterococcus faecium, accompanied by bacteremia as well
StageMA
Year completed2015
Product TypeINN - Linezolid
IndicationInfectious-inflammatory diseases caused by microorganisms sensitive to the drug
StageMA
Year completed2015
Product TypeFDC - Amoxicillin + Clavulanic acid
IndicationInfection caused by the virus Varicella Zoster and Herpes simplex type I and II
StageMA
Year completed2015
Product TypeINN - Famciclovir
IndicationСorneal ulcers and infections of the anterior segment of the eyeball and its adnexa caused by susceptible to ciprofloxacin bacteria in adults, newborns, babies and infants, children and adolescents
StageMA
Year completed2015
Product TypeINN - Ciprofloxacin
IndicationHIV 1 infection in adults in combination therapy with other antiretroviral drugs
StageMA
Year completed2015
Product TypeINN - Nevirapine
IndicationCMV (cytomegalovirus) retinitis in AIDS patients; prevention of CMV infection after transplantation of solid organs in patients from high risk groups
StageBE/PK
Year completed2015
Product TypeINN - Valganciclovir
IndicationHIV-1 and HIV-2 infections in adults in the complex therapy with other antiretroviral drugs
StageBE/PK
Year completed2015
Product TypeFDC - Tenofovir + Emtricitabine
IndicationInfections of upper and lower respiratory tract; infections of the urinary tract and kidneys; chronic bacterial prostatitis; infections of skin and soft tissue; intra-abdominal infections; tuberculosis (complex therapy of drug-resistant forms)
StageBE/PK
Year completed2015
Product TypeINN - Levofloxacin
IndicationInfectious-inflammatory diseases, caused by susceptible to linezolid aerobic and anaerobic gram-positive microorganisms: community-acquired pneumonia caused by Streptococcus pneumoniae; hospital-acquired pneumonia; complicated infections of skin and soft tissues; uncomplicated skin infections and soft tissue infections caused by resistant to vancomycin Enterococcus faecium, accompanied by bacteremia as well
StageBE/PK
Year completed2015
Product TypeINN - Linezolid
IndicationBacterial infections of upper and lower respiratory tract, urinary tract, skin and soft tissues, bones and joints, others
StageBE/PK
Year completed2015
Product TypeFDC - Amoxicillin + Clavulanic acid
IndicationHIV/AIDS
StageBE/PK
Year completed2015
Product TypeFDC - Abacavir + Lamivudine
IndicationHIV/AIDS
StageBE/PK
Year completed2015
Product TypeINN - Abacavir
IndicationHIV/AIDS
StageMA
Year completed2015
Product TypeINN - Stavudine
IndicationHIV/AIDS
StageBE/PK
Year completed2015
Product TypeFDC - Abacavir + Lamivudine
IndicationHerpes Zoster, infection and prevention of recurrent infections of skin and mucous membranes caused by herpes simplex; prevention of transmission of genital herpes uninfected partner; prevention of cytomegaloviruses infection, and reactions of acute transplant rejection, opportunistic infections and other (herpes simplex, Herpes Zoster) infections after organ transplantation
StageBE/PK
Year completed2015
Product TypeINN - Valaciclovir
IndicationBacterial infections of upper and lower respiratory tract, urinary tract, female genital organs, skin and soft tissues, bones and joints, others; prevention of postoperative infections in surgical interventions
StageMA
Year completed2015
Product TypeFDC - Amoxicillin + Clavulanic acid
IndicationInfectious-inflammatory diseases caused by sensitive to moxifloxacin microorganisms: acute sinusitis; exacerbation of chronic bronchitis; community-acquired pneumonia; infections of skin and soft tissues; complicated intraabdominal infections
StageMA
Year completed2015
Product TypeINN - Moxifloxacin
IndicationHIV/AIDS
StageMA
Year completed2015
Product TypeINN - Efavirenz
IndicationBacterial infections caused by pathogens susceptible to the FDC: infections of upper and lower respiratory tract; urinary tract infections, infections of the female genital organs, gonorrhea; infections of skin and soft tissues; infections of bones and joints; septic abortion, puerperal sepsis, septicaemia, peritonitis, intraabdominal sepsis, postoperative infection
StageMA
Year completed2015
Product TypeFDC - Amoxicillin + Clavulanic acid
IndicationInfection caused by the virus Varicella Zoster and Herpes simplex type I and II
StageBE/PK
Year completed2014
Product TypeINN - Famciclovir
IndicationHIV/AIDS
StageBE/PK
Year completed2014
Product TypeINN - Efavirenz
IndicationHIV/AIDS
StageMA
Year completed2014
Product TypeINN - Efavirenz
IndicationHIV/AIDS
StageMA
Year completed2014
Product TypeFDC - Lamivudine + Zidovudine
IndicationHIV/AIDS
StageMA
Year completed2014
Product TypeINN - Darunavir
IndicationHIV/AIDS
StageBE/PK
Year completed2014
Product TypeINN - Abacavir
IndicationInfections of skin and soft tissues
StagePhase III CT
Year completed2014
Product TypeINN - Teicoplanin (glycopeptide)
IndicationHIV/AIDS
StageBE/PK
Year completed2013
Product TypeINN - Efavirenz
IndicationHIV/AIDS
StageBE/PK
Year completed2013
Product TypeINN - Darunavir
IndicationHIV/AIDS
StageBE/PK
Year completed2013
Product TypeINN - Zidovudine + Lamivudine
IndicationHIV/AIDS
StageBE/PK
Year completed2013
Product TypeINN - Lamivudine
IndicationTuberculosis, extrapulmonary tuberculosis, atypical mycobacterial infections
StageBE/PK
Year completed2013
Product TypeINN - Cycloserine
IndicationHIV/AIDS
StageMA
Year completed2013
Product TypeINN - Lamivudine
IndicationInfections of ENT organs, infections of the lower respiratory tract, infections of the urinary tract and kidneys, chronic bacterial prostatitis, infections of skin and soft tissues , intra-abdominal infections
StageBE/PK
Year completed2013
Product TypeINN - Levofloxacin
IndicationChronic hepatitis B, HIV/AIDS
StageBE/PK
Year completed2013
Product TypeINN - Lamivudine
IndicationChronic hepatitis B, HIV/AIDS
StageBE/PK
Year completed2013
Product TypeINN - Lamivudine
IndicationInfections of the lower respiratory tract, urinary tract infections, intraabdominal infections, infections of skin and soft tissues, septicemia, gynecologic infections, bacterial infections in patients with neutropenia, infections of bones and joints
StageMA
Year completed2012
Product TypeFDC - Piperacillin + Tazobactam
IndicationInfections of upper and lower respiratory tract infections, infections of skin and soft tissues
StageMA
Year completed2012
Product TypeINN - Clarithromycin
IndicationCommunity-acquired pneumonia; complicated infections of skin and soft tissue, complicated intraabdominal infections
StageMA
Year completed2012
Product TypeINN - Moxifloxacin
IndicationInfections of the lower respiratory tract, urinary tract infections, intraabdominal infections, infections of skin and soft tissues, septicemia, gynecologic infections, bacterial infections in patients with neutropenia, infections of bones and joints
StageMA
Year completed2012
Product TypeFDC - Piperacillin + Tazobactam
IndicationInfections of lower respiratory tract, infections of urinary system, infections of skin and soft tissue, infection of pelvic organs, bacterial meningitis
StageMA
Year completed2011
Product TypeINN - Meropenem
IndicationBacterial infections of upper and lower respiratory tract, urinary tract, female genital organs, skin and soft tissues, bones and joints, others; prevention of postoperative infections in surgical interventions
StageMA
Year completed2011
Product TypeFDC - Amoxicillin + Clavulanic acid
IndicationAmebiasis, bacterial infection
StageMA
Year completed2011
Product TypeINN - Ornidazole

Inflammatory

Indication
Stage
Year completed
Product Type
IndicationOsteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis
StageBE/PK
Year completedpresent
Product TypeINN - Etoricoxib
IndicationСomplex therapy of osteoarthritis of the knee or hip joint
StagePhase III CT / Medical writing
Year completed2018
Product TypeBranded pharmaceutical (botanical)
IndicationOsteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis
StageBE/PK + MA
Year completed2017 + 2018
Product TypeINN - Etoricoxib
IndicationInflammatory and degenerative diseases of the musculoskeletal system
StagePVG
Year completed2017
Product TypeINN - Diclofenac
IndicationOsteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis
StageBE/PK
Year completed2017
Product TypeINN - Etoricoxib
IndicationInflammatory and degenerative diseases of the musculoskeletal system
StageVariation
Year completed2017
Product TypeINN - Ketoprofen
IndicationInflammatory and degenerative diseases of the musculoskeletal system
StagePVG / PSUR
Year completed2017
Product TypeINN - Diclofenac
IndicationOsteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis
StageBE/PK + MA
Year completed2017
Product TypeINN - Etoricoxib
IndicationInfectious-inflammatory diseases caused by sensitive to imipenem microorganisms
StageMA
Year completed2014
Product TypeFDC - Imipenem + Cilastatin
IndicationAcute pain in the postoperative period - appendectomy
StagePhase III CT
Year completed2014
Product TypeINN - Paracetamol
IndicationPain of moderate intensity in postoperative period and short-term relief of fever
StageMA
Year completed2012
Product TypeINN - Paracetamol
IndicationInflammatory and degenerative diseases of the musculoskeletal system
StageMA
Year completed2011
Product TypeINN - Diclofenac

Intensive care

Indication
Stage
Year completed
Product Type
IndicationMyorelaxation for performing the intubation and artificial lung ventilation, skeletal muscle relaxation during surgery and mechanical ventilation in intensive care units
StageMA
Year completed2014
Product TypeINN - Atracurium besilate

Metabolic diseases

Indication
Stage
Year completed
Product Type
IndicationNon-insulin dependent diabetes mellitus
StageBE/PK
Year completedpresent
Product TypeFDC - Vildagliptin + Metformin 50 + 1000
IndicationNon-insulin dependent diabetes mellitus
StageBE/PK
Year completedpresent
Product TypeFDC - Vildagliptin + Metformin 50 + 850
IndicationNon-insulin dependent diabetes mellitus
StageBE/PK
Year completedpresent
Product TypeFDC - Vildagliptin + Metformin 50 + 500
IndicationNon-insulin dependent diabetes mellitus
StageBE/PK
Year completedpresent
Product TypeINN - Vildagliptin
IndicationHypo - and avitaminosis of vitamin D
StageMA
Year completedpresent
Product TypeINN - Colecalciferol
IndicationHypercholesterolemia, hypertriglyceridemia
StageBE/PK + MA
Year completed2018 + 2019
Product TypeINN - Rosuvastatin
IndicationShock; cerebral edema; bronchial asthma, asthma status; systemic diseases of connective tissue; thyrotoxic crisis; hepatic coma; poisoning with cauterizing liquids; acute and chronic inflammatory diseases of the joints; others
StageRenewal
Year completed2017
Product TypeINN - Dexamethasone
IndicationOsteoarthritis of the peripheral joints and spine
StageRenewal
Year completed2017
Product TypeFDC - Glucosamine + Chondroitin sulfate + Vitamin E
IndicationMegaloblastic anemia; tropical and non-tropical sprue, drug and radiation anemia and leukopenia, chronic gastroenteritis, intestinal tuberculosis, folic acid
StageVariation
Year completed2017
Product TypeINN - Folic acid
IndicationOsteoporosis, osteomalacia, hypocalcemia
StageVariation
Year completed2017
Product TypeFDC - Calcium carbonate + Colecalciferol
IndicationFolic acid + Vitamin B12 deficiency
StageVariation
Year completed2017
Product TypeFDC - Folic acid + Сyanocobalamin (B12)
IndicationIron-deficiency
StageMA
Year completed2017
Product TypeINN - Ferric (III) hydroxide sacharose complex
IndicationHypercholesterolemia, hypertriglyceridemia
StageMA
Year completed2017
Product TypeINN - Rosuvastatin
IndicationParenteral nutrition
StageVariations
Year completed2017
Product TypeBioanalogue - Human albumin
IndicationIron deficiency
StageVariation
Year completed2016
Product TypeINN - Ferrous protein succinilate
IndicationB vitamins
StageRenewal
Year completed2016
Product TypeFDC - Potassium iodide+Folic acid+Cyanocobalamin
IndicationHypercholesterolemia, hypertriglyceridemia
StageBE/PK
Year completed2016
Product TypeINN - Rosuvastatin
IndicationSecondary hyperparathyroidism in patients with ESRD undergoing dialysis. hypercalcemia
StageMA
Year completed2016
Product TypeINN - Cinacalcet
IndicationShock; cerebral edema; bronchial asthma, asthma status; systemic diseases of connective tissue; thyrotoxic crisis; hepatic coma; poisoning with cauterizing liquids; acute and chronic inflammatory diseases of the joints; others
StageED price registration
Year completed2015
Product TypeINN - Dexamethasone
IndicationSecondary hyperparathyroidism in patients with end-stage renal failure who are on dialysis; hypercalcemia in patients caused by carcinoma of the parathyroid glands, by primary hyperparathyroidism
StageBE/PK
Year completed2015
Product TypeINN - Cinacalcet
IndicationIntense physical exertion and emotional stress; chronic gastritis and chronic pancreatitis, skin diseases, etc - in complex therapy
StagePreclinical
Year completed2013
Product TypeINN - Levocarnitine

Nephrology / Cardiovascular

Indication
Stage
Year completed
Product Type
IndicationEssential hypertension, nephropathy caused by arterial hypertension and diabetes mellitus type II
StageMA
Year completed2016
Product TypeINN - Irbesartan
IndicationEssential hypertension, nephropathy caused by arterial hypertension and diabetes mellitus type II
StageBE/PK
Year completed2015
Product TypeINN - Irbesartan

Nutrition

Indication
Stage
Year completed
Product Type
IndicationSource of zinc
StageMA
Year completed2018
Product TypeDietary supplement - Source of zinc
IndicationAdditional source of calcium and vitamins D and B group, source of isoflavones
StageMA
Year completed2017
Product TypeDietary supplement
IndicationAdditional source of vitamins, minerals and polyunsaturated fatty acids family omega-3 for pregnant and lactating women
StageMA
Year completed2017
Product TypeDietary supplement

Oncology

Indication
Stage
Year completed
Product Type
IndicationNon-small cell lung cancer, breast cancer; prostate cancer resistant to hormone therapy
StageMA
Year completedpresent
Product TypeINN - Vinorelbine
IndicationLocally advanced or metastatic non-small cell lung cancer; unresectable, locally recurrent or metastatic breast cancer; locally advanced or metastatic urothelial cancer; others
StageMA
Year completedpresent
Product TypeINN - Gemcitabine
IndicationGeneralized malignant lymphoma, multiple myeloma
StageMA
Year completedpresent
Product TypeINN - Bendamustine
IndicationColon and rectal cancer, breast cancer, esophagus, stomach, pancreas, primary liver cancer, bladder cancer, prostate cancer, ovarian cancer, cervical cancer, head and neck cancer, adrenal cancer, vulva cancer, penile cancer, carcinoid
StageMA
Year completedpresent
Product TypeINN - Fluorouracil
IndicationBreast cancer, lung cancer
StageMA
Year completedpresent
Product TypeINN - Docetaxel
IndicationSkin cancer, head and neck cancer, cancer of penis, vulva, cervix, lung, esophagus, germ cell tumors of testis and ovary, teratocarcinoma , kidney cancer, malignant lymphoma, reticulosarcoma, glioma, etc.
StageMA
Year completedpresent
Product TypeINN - Bleomycin
IndicationMultiple Myeloma
StageMA
Year completedpresent
Product TypeBioanalogue - Bortezomib
IndicationLocally advanced or metastatic cancer of the colon and rectum
StageMA
Year completedpresent
Product TypeINN - Irinotecan
IndicationDisseminated breast cancer with overexpression of HER2
StageMA
Year completedpresent
Product TypeBiosimilar - Trastuzumab
IndicationInoperable or metastatic melanoma; locally advanced or metastatic non-small cell lung cancer after prior chemotherapy; common renal cell cancer after prior systemic therapy
StageMA / Consulting
Year completedpresent
Product TypeBiologic - Nivolumab
IndicationNon-Hodgkin's lymphoma
StageMA
Year completedpresent
Product TypeBiosimilar - Rituximab
IndicationHypercalcemia, bone metastases in malignant solid tumors, postmenopausal osteoporosis
StageMA
Year completedpresent
Product TypeINN - Zoledronic acid
IndicationMyelodysplastic syndrome
StageMA
Year completedpresent
Product TypeINN - Decitabine
IndicationMyelodysplastic syndrome
StageMA
Year completedpresent
Product TypeINN - Azacitidine
IndicationPalliative treatment of progressive prostate cancer, treatment of locally advanced prostate cancer, differential diagnosis of hypogonadism in men
StageMA
Year completedpresent
Product TypeINN - Flutamide
IndicationGerm cell tumors of testis and ovary, lung cancer , cancer of the adrenal cortex, bladder cancer, acute monoblastic and myeloblastic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, Kaposi's sarcoma, Ewing's sarcoma, gastric cancer, horionepitelioma, neuroblastoma
StageMA
Year completedpresent
Product TypeINN - Etoposide
IndicationMalignant neoplasms
StageMA
Year completedpresent
Product TypeINN - Methotrexate
IndicationCancer of ovary, prostate, bladder and renal pelvis, breast, body and cervix, horionepitelioma cancer, skin cancer, neuroblastoma, Hodgkin's disease, lymphoma, melanoma, soft tissue sarcoma, osteosarcoma, metastatic ascites, germ cell tumors, etc.
StageMA
Year completedpresent
Product TypeINN - Cisplatin
IndicationOvarian cancer, germ cell tumors, lung cancer, malignant neoplasms of head and neck, cervical and endometrial, breast, bladder, soft tissue sarcoma, melanoma
StageMA
Year completed2019
Product TypeINN - Carboplatin
IndicationSkin cancer, head and neck cancer, cancer of penis, vulva, cervix, lung, esophagus, germ cell tumors of testis and ovary, teratocarcinoma , kidney cancer, malignant lymphoma, reticulosarcoma, glioma, etc.
StageMA
Year completed2019
Product TypeINN - Bleomycin
IndicationSmall cell lung cancer, ovarian cancer, cervical and endometrial, breast, bladder, prostate cancer; neuroblastoma, retinoblastoma, angiosarcoma, reticulosarcoma, lymphosarcoma, leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, myeloma, etc.
StageMA
Year completed2019
Product TypeINN - Cyclophosphamide
IndicationMultiple myeloma, anemia in patients dependent on blood transfusions, Mantle Cell Lymphoma
StageMA / CTD
Year completed2018
Product TypeINN - Lenalidomide
IndicationChronic myeloid leukemia, acute lymphoblastic leukemia
StageMA / CTD
Year completed2018
Product TypeINN - Dasatinib
IndicationChronic myeloid leukemia
StageMA / CTD
Year completed2018
Product TypeINN - Nilotinib
IndicationGeneralized malignant lymphoma, multiple myeloma
StageMA
Year completed2018
Product TypeINN - Bendamustine
IndicationLocally advanced or metastatic non-small cell lung cancer
StageBE/PK
Year completed2018
Product TypeINN - Gefitinib
IndicationRenal cell carcinoma
StageBE/PK (pnts)
Year completed2018
Product TypeINN - Pazopanib
IndicationMalignant neoplasms
StageMA
Year completed2018
Product TypeINN - Hydroxycarbamide
IndicationMalignant neoplasms
StageMA
Year completed2018
Product TypeINN - Methotrexate
IndicationHodgkin's disease, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, multiple myeloma, ovarian cancer, breast cancer, etc.
StageMA
Year completed2018
Product TypeINN - Chlorambucil
IndicationBreast cancer, endometrial cancer
StageMA
Year completed2018
Product TypeINN - Tamoxifen
IndicationSarcoma, breast cancer, small cell lung cancer, thyroid cancer, malignant thymoma, esophageal cancer, hepatoblastoma, primary hepatocellular cancer, gastric cancer, pancreatic cancer, ovarian cancer, neuroblastoma, endometrial cancer, cervical cancer, prostate cancer, etc.
StageMA
Year completed2018
Product TypeINN - Doxorubicin
IndicationLocally advanced or metastatic non-small cell lung cancer, solid tumors
StageBE/PK
Year completed2018
Product TypeINN - Gefitinib
IndicationRelapsed or refractory lymphoma
StageBE/PK
Year completed2018
Product TypeINN - Ibrutinib
IndicationCommon and/or metastatic breast tumor with overexpression of HER2
StageBE/PK (pnts)
Year completed2018
Product TypeINN - Lapatinib
IndicationСommon renal cell carcinoma
StageBE/PK
Year completed2018
Product TypeINN - Pazopanib
IndicationMetastatic castration-resistant prostate cancer
StageMA
Year completed2017
Product TypeINN - Abiraterone
IndicationMetastatic castrate-resistant prostate cancer
StageBE/PK
Year completed2017
Product TypeINN - Abiraterone
IndicationLocally advanced or metastatic non-small cell lung cancer
StageBE/PK
Year completed2017
Product TypeINN - Gefitinib
IndicationBreast cancer, colorectal cancer, stomach cancer
StageBE/PK
Year completed2017
Product TypeINN - Capecitabine
IndicationGlioma, glioblastoma, common metastatic malignant melanoma
StageRenewal
Year completed2017
Product TypeINN - Temozolomide
IndicationMetastatic renal cell carcinoma; hepatocellular cancer; locally-common or metastatic differentiated thyroid cancer resistant to radioactive iodine
StageBE/PK
Year completed2017
Product TypeINN - Sorafenib
IndicationCancer of ovary, prostate, bladder and renal pelvis, breast, body and cervix, horionepitelioma cancer, skin cancer, neuroblastoma, Hodgkin's disease, lymphoma, melanoma, soft tissue sarcoma, osteosarcoma, metastatic ascites, germ cell tumors, etc.
StageMA
Year completed2017
Product TypeINN - Cisplatin
IndicationMetastatic castration-resistant prostate cancer
StageBE/PK
Year completed2017
Product TypeINN - Abiraterone
IndicationGlioma, glioblastoma, common metastatic malignant melanoma
StageBE/PK (medical writing)
Year completed2016
Product TypeINN - Temozolomide
IndicationСhronic myeloid leukemia (CML) in adults and children; acute lymphoblastic leukemia (ALL) in adults in combination with chemotherapy; recurrent or refractory Ph+ ALL in adults as monotherapy; myelodysplastic / myeloproliferative diseases associated with genetic rearrangements of the receptor of the platelet growth factor in adults; systemic mastocytosis in adults; hypereosinophilic syndrome and / or chronic eosinophilic leukemia in adults; unresectable and / or metastatic malignant gastrointestinal stromal tumors; unresectable, recurrent and / or metastatic dermatofibrosarcoma in adults
StageMA
Year completed2016
Product TypeINN - Imatinib
IndicationСhronic myeloid leukemia (CML) in adults and children; acute lymphoblastic leukemia (ALL) in adults in combination with chemotherapy; recurrent or refractory Ph+ ALL in adults as monotherapy; myelodysplastic / myeloproliferative diseases associated with genetic rearrangements of the receptor of the platelet growth factor in adults; systemic mastocytosis in adults; hypereosinophilic syndrome and / or chronic eosinophilic leukemia in adults; unresectable and / or metastatic malignant gastrointestinal stromal tumors; unresectable, recurrent and / or metastatic dermatofibrosarcoma in adults
StageBE/PK
Year completed2016
Product TypeINN - Imatinib
IndicationGastrointestinal stromal tumors; common and/or metastatic renal cell carcinoma
StageBE/PK
Year completed2016
Product TypeINN - Sunitinib
IndicationMultiple myeloma
StageBE/PK
Year completed2016
Product TypeINN - Lenalidomide
IndicationChronic myeloid leukemia
StageBE/PK
Year completed2016
Product TypeINN - Nilotinib
IndicationBreast cancer, lung cancer
StagePhase III CT
Year completed2016
Product TypeINN - Docetaxel
IndicationNon-small cell lung cancer and pancreatic сancer
StageМА
Year completed2015
Product TypeINN - Erlotinib
IndicationNon-small cell lung cancer, pancreatic cancer
StageBE/PK
Year completed2015
Product TypeINN - Erlotinib
IndicationСhronic myeloid leukemia (CML) in adults and children; acute lymphoblastic leukemia (ALL) in adults in combination with chemotherapy; recurrent or refractory Ph+ ALL in adults as monotherapy; myelodysplastic / myeloproliferative diseases associated with genetic rearrangements of the receptor of the platelet growth factor in adults; systemic mastocytosis in adults; hypereosinophilic syndrome and / or chronic eosinophilic leukemia in adults; unresectable and / or metastatic malignant gastrointestinal stromal tumors; unresectable, recurrent and / or metastatic dermatofibrosarcoma in adults
StageMA
Year completed2014
Product TypeINN - Imatinib
IndicationBreast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, gastric cancer, head and neck cancer
StageMA
Year completed2014
Product TypeINN - Docetaxel
IndicationBreast cancer
StageMA
Year completed2012
Product TypeINN - Letrozole
IndicationBreast cancer
StageMA
Year completed2012
Product TypeINN - Anastrozole
IndicationBladder cancer, breast cancer, head and neck cancer, acute leukemia, NSCLC, non-Hodgkin's lymphoma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, others
StageMA
Year completed2011
Product TypeINN - Epirubicin
IndicationLung cancer, arterially cancer, ovarian cancer, pancreatic cancer, cervical cancer, breast cancer
StageMA
Year completed2010
Product TypeINN - Gemcitabine
IndicationGlioma, glioblastoma, common metastatic malignant melanoma
StageMA
Year completed2010
Product TypeINN - Temozolomide

Ophthalmology

Indication
Stage
Year completed
Product Type
IndicationElevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
StageMA
Year completed2017
Product TypeINN - Dorzolamide
IndicationReduction of elevated intraocular pressure in patients with ocular hypertension and open-angle glaucoma, aphakic glaucoma, secondary glaucomas
StageMA
Year completed2015
Product TypeINN - Timolol
IndicationPrimary open-angle glaucoma
StagePhase III CT
Year completed2015
Product TypeINN - Latanoprost
IndicationPrimary open-angle glaucoma
StagePhase III CT
Year completed2015
Product TypeINN - Travoprost
IndicationAcute bacterial conjunctivitis
StagePhase III CT
Year completed2014
Product TypeINN - Moxifloxacine hydrochloride
IndicationPurulent-inflammatory diseases of the eye (conjunctivitis)
StagePhase III CT
Year completed2014
Product TypeINN - Tobramycin

Parasitic diseases

Indication
Stage
Year completed
Product Type
IndicationNematodosis, mixed helminthic infestations, strongyloidiasis, neurocysticercosis, echinococcosis of liver, lungs, and peritoneum, giardiasis, toxocariasis
StageBE/PK
Year completed2017
Product TypeINN - Albendazole

Pediatrics

Indication
Stage
Year completed
Product Type
IndicationAttention deficit hyperactive disorder (CNS)
StagePhase III CT / study design+ MA / substantial vaiation
Year completed2018 + present
Product TypeINN - Ethylmethylhydroxypyridine succinate
IndicationFunctional bowel disorders, accompanied by abdominal pain with intestinal colic and flatulence (gastroenterology)
StageMA
Year completed2011
Product TypeHomeopathic

Radiology

Indication
Stage
Year completed
Product Type
IndicationAngiocardiography, aortography, angiography, others
StageMA
Year completedpresent
Product TypeINN - Iohexol

Respiratory

Indication
Stage
Year completed
Product Type
IndicationAsthma
StagePhase II CT
Year completedpresent
Product TypeBranded pharmaceutical
IndicationAcute and chronic bronchopulmonary diseases, accompanied by difficulty of sputum discharge
StageMA
Year completedpresent
Product TypeFDC - Bromhexine + Guaifenesin + Salbutamol + Racementhol
IndicationAcute bronchitis
StagePhase III CT (medical writing)
Year completed2019
Product TypeFDC - Ambroxol + Acetylcysteine
IndicationBronchial asthma, seasonal and perennial allergic rhinitis
StageMA
Year completed2017
Product TypeINN - Montelukast

Respiratory / Infectious diseases

Indication
Stage
Year completed
Product Type
IndicationAcute respiratory infection
StagePhase III CT
Year completedpresent
Product TypeFDC - Ambroxol + Salbutamol + Guaifenesin
IndicationPulmonary tuberculosis, extrapulmonary tuberculosis, atypical mycobacterial infection including those caused by Mycobacterium avium; acute urinary tract infections caused by susceptible strains of gram-positive and gram-negative bacteria, especially Klebsiella spp. Enterobacter spp and Escherichia coli
StageBE/PK
Year completed2017
Product TypeINN - Cycloserine
IndicationTuberculosis of various forms and localizations
StageMA
Year completed2017
Product TypeINN - Aminosalicylic acid
IndicationDrug-resistant forms of tuberculosis
StageMA
Year completed2016
Product TypeINN - Terizidone
IndicationTuberculosis
StageMA
Year completed2016
Product TypeINN - Terizidone
IndicationDrug-resistant forms of tuberculosis
StageMA
Year completed2016
Product TypeINN - Terizidone
IndicationLower respiratory tract infections, acute bacterial sinusitis, others
StageED price registration
Year completed2015
Product TypeINN - Levofloxacin
IndicationNosocomial pneumonia caused metitsillinrezistentnye strains of Staphylococcus aureus
StagePhase III MMCT
Year completed2015
Product TypeINN - Linezolid
IndicationDrug-resistant tuberculosis of various forms and localization
StageMA
Year completed2015
Product TypeFDC - Terizidone + Pyridoxine
IndicationDrug-resistant tuberculosis of various forms and localization
StageBE/PK
Year completed2015
Product TypeINN - Aminosalicylic acid
IndicationDrug-resistant tuberculosis of various forms and localization
StageBE/PK
Year completed2015
Product TypeINN - Terizidone
IndicationInfectious-inflammatory diseases caused by sensitive to levofloxacin by micro-organisms: lower respiratory tract infection; acute maxillary sinusitis; uncomplicated urinary tract infections; complicated urinary tract infections; infections of skin and soft tissue; septicemia / bacteremia; chronic bacterial prostatitis; intra-abdominal infection; complex therapy of drug-resistant forms of tuberculosis
StageMA
Year completed2014
Product TypeINN - Levofloxacin
IndicationTuberculosis of different forms and locations (in combination with other anti-TB drugs), including multidrug-resistance to other anti-TB drugs
StageMA
Year completed2014
Product TypeINN - Aminosalicylic acid
IndicationDrug-resistant tuberculosis of various forms and localization
StageBE/PK
Year completed2014
Product TypeFDC - Terizidone + Pyridoxine
IndicationTuberculosis
StageBE/PK
Year completed2013
Product TypeFDC - Cycloserine + Pyridoxine
IndicationDrug-resistant tuberculosis of various forms and localization
StageMA
Year completed2013
Product TypeINN - Aminosalicylic acid
IndicationDrug-resistant tuberculosis of various forms and localization
StageMA
Year completed2013
Product TypeINN - Terizidone
IndicationDrug-resistant tuberculosis of various forms and localization
StageMA
Year completed2012
Product TypeINN - Terizidone
IndicationTuberculosis of various localizations
StageMA
Year completed2012
Product TypeFDC - Isoniazid + Pyrazinamide + Rifampicin
IndicationColds, flu, acute respiratory viral diseases
StageMA
Year completed2012
Product TypeFDC - Caffeine + Paracetamol + Phenylephrine + Chlorphenamine
IndicationTuberculosis
StageBE/PK
Year completed2012
Product TypeINN – Terizidone
IndicationTuberculosis
StageBE/PK
Year completed2012
Product TypeINN - Terizidone
IndicationTuberculosis of various forms and localizations
StageMA
Year completed2011
Product TypeINN - Aminosalicylic acid
IndicationAcute respiratory diseases
StageMA
Year completed2011
Product TypeBotanical drug - Anti-cold drug
IndicationPulmonary tuberculosis
StageMA
Year completed2011
Product TypeINN - Capreomycin
IndicationTuberculosis, atypical mycobacterial infection, urinary tract infection
StageMA
Year completed2011
Product TypeINN - Cycloserine
IndicationLower respiratory tract infections, acute bacterial sinusitis, others
StageMA
Year completed2010
Product TypeINN - Levofloxacin

Rheumatology

Indication
Stage
Year completed
Product Type
IndicationAnti-inflammatory, antipyretic, analgesic
StageMA
Year completed2017
Product TypeINN - Meloxicam
IndicationOsteoarthritis, rheumatoid arthritis, ankylosing spondylitis, back pain, musculoskeletal, postoperative and other types of pain, primary dysmenorrhea
StageBE/PK
Year completed2017
Product TypeINN - Celecoxib
IndicationOsteoarthritis, rheumatoid arthritis and ankylosing spondylitis, pain syndrom, primary dysmenorrhea
StageBE/PK
Year completed2015
Product TypeINN - Celecoxib
IndicationRheumatoid arthritis, osteoarthritis, arthritis of various etiologies, arthralgia, myalgia, postoperative and posttraumatic pain, bursitis, tendonitis, dysmenorrhoea, dental and headache
StageMA
Year completed2013
Product TypeINN - Nimesulide
IndicationOsteoarthritis of I-III stages of peripheral joints and spine.
StageMA
Year completed2012
Product TypeFDC - Glucosamine sulphate + Chondroitin sulfate Potassium Adipate + Vitamin E

Stomatology

Indication
Stage
Year completed
Product Type
IndicationStomatitis and gingivitis
StagePhase III CT + MA
Year completedpresent
Product TypeFDC - Lysocime + Pyridoxine

Transplantology

Indication
Stage
Year completed
Product Type
IndicationRejection of the allograft liver, kidney and heart
StageMA
Year completed2016
Product TypeINN - Tacrolimus
IndicationRejection of the allograft liver, kidney and heart
StageMA
Year completed2012
Product TypeINN - Tacrolimus
IndicationAcute rejection of allogeneic transplant kidney
StageMA
Year completed2012
Product TypeINN - Mycophenolate mofetil

Urology

Indication
Stage
Year completed
Product Type
IndicationRenal failure
StageMA
Year completed2018
Product TypeINN - Ketoanalogues of aminoacids
IndicationOveractive bladder syndrome
StageBE/PK
Year completed2017
Product TypeINN - Solifenacin

Various

Indication
Stage
Year completed
Product Type
IndicationRussian GMP inspection
StageGMP
Year completedpresent
Product TypeDiagnostics
IndicationRussian GMP inspection
StageGMP
Year completedpresent
Product TypeBioanalogues
IndicationRussian GMP inspection
StageGMP
Year completedpresent
Product TypeGenerics
IndicationRussian GMP inspection
StageGMP
Year completed2017
Product TypeGenerics
IndicationRussian GMP inspection
StageGMP
Year completed2017
Product TypemAbs